Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)

This study has been completed.

Sponsor:

Information provided by:

Merck

ClinicalTrials.gov Identifier:

NCT00092521

First received: September 23, 2004

Last updated: April 7, 2010

Last verified: April 2010

History of Changes

Results First Received: August 3, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Prevention
Conditions:	Cervical Cancer Genital Warts
Interventions:	Biological: V501 Biological: Comparator: Placebo Biological: Human Papillomavirus (HPV) 16 Monovalent

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study Protocol 013 (NCT00092521) (N =5759 total randomized) was compromised of two sub-studies: Protocol 011 (NCT00517309) (N=1877 total randomized) and Protocol 012 (NCT00092482) (N=3882 total randomized). Final safety data are presented in the results for Protocol 013 (NCT00092521).

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent Human papillomavirus (HPV) vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Group 2 - Base Study Monovalent HPV (Type 16) Vaccine	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with the Monovalent (HPV 16) HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Monovalent (HPV 16) HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study. Group 2 Base Study Monovalent HPV (Type 16) Vaccine was not part of the pre-specified efficacy analysis population.
Group 3 - Base Study Placebo	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Group 4 - Quadrivalent Human Papillomavirus Vaccine Extension	This group includes 844 subjects who entered the extension including subjects who in the base study received fewer than the full three doses of Quadrivalent HPV vaccine during the base study (i.e., subjects who received placebo in the base study; subjects who received monovalent [type 16] HPV vaccine in the base study, or subjects who received ≥ 2 doses of quadrivalent HPV vaccine in the base study). Subjects who discontinued the base portion of the study could enter the extension portion of the study. In the extension period subjects designated as "Completed Period" are those who received three doses of quadrivalent HPV vaccine and completed all required follow-up visits. Subjects designated as "Not Completed" are those who: a) Received all three vaccinations, but did not complete follow-up; b) Did not receive all vaccinations, but completed follow-up, or c) Did not receive all vaccinations, and did not complete follow-up).

Participant Flow for 3 periods

Period 1: Vaccination (Day 1 Through Month 7)

	Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine	Group 2 - Base Study Monovalent HPV (Type 16) Vaccine	Group 3 - Base Study Placebo
STARTED	2723	304	2732
COMPLETED	2582	290	2587
NOT COMPLETED	141	14	145
Randomized Not Vaccinated	6	0	7
Adverse Event	1	0	7
Death	1	0	0
Lost to Follow-up	51	6	44
Pregnancy	5	0	7
Withdrawal by Subject	59	7	62
Moved	14	1	18
Unblinded	2	0	0
New Medical History (Not AE)	2	0	0

Period 2: Follow-Up (After Month 7)

	Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine	Group 2 - Base Study Monovalent HPV (Type 16) Vaccine	Group 3 - Base Study Placebo
STARTED	2599 ^[1]	291 ^[1]	2607 ^[1]
COMPLETED	2354	155	1959
NOT COMPLETED	245	136	648
Subjects Continuing	34	4	35
Subjects in Extension	13	109	412
Adverse Event	1	0	0
Death	1	0	1
Lost to Follow-up	113	14	108
Protocol Violation	1	1	5
Withdrawal by Subject	40	6	51
Moved	32	2	28
Site Terminated	3	0	3
Travel	2	0	0
Visits Compressed	5	0	5

[1]	Includes subjects who did not receive 3 doses of vaccine/placebo but continued into the follow-up

Period 3: Extension Study (Group 4)

	Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine	Group 2 - Base Study Monovalent HPV (Type 16) Vaccine	Group 3 - Base Study Placebo	Group 4 - Quadrivalent Human Papillomavirus Vaccine Extension
STARTED	0	0	0	844
COMPLETED	0	0	0	635
NOT COMPLETED	0	0	0	209
Excluded ineligible for extension	0	0	0	23
Adverse Event	0	0	0	2
Lost to Follow-up	0	0	0	87
Pregnancy	0	0	0	4
Protocol Violation	0	0	0	2
Withdrawal by Subject	0	0	0	46
Moved	0	0	0	16
Site Terminated	0	0	0	4
Unable/unwilling to return	0	0	0	25

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Group 2 - Base Study Monovalent HPV (Type 16) Vaccine	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with the Monovalent (HPV 16) HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Monovalent (HPV 16) HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Group 3 - Base Study Placebo	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Total	Total of all reporting groups

Baseline Measures

	Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine	Group 2 - Base Study Monovalent HPV (Type 16) Vaccine	Group 3 - Base Study Placebo	Total
Number of Participants [units: participants]	2723	304	2732	5759
Age, Customized ^[1] [units: Participants]
16 to 24 Years of Age	2723	304	2732	5759
Age [units: years] Mean ± Standard Deviation	20.2 ± 1.8	20.2 ± 1.74	20.3 ± 1.8	20.3 ± 1.8
Age [units: Years] Median ( Full Range )	20 ( 16 to 24 )	20 ( 16 to 24 )	20 ( 16 to 24 )	20 ( 16 to 24 )
Gender [units: participants]
Female	2723	304	2732	5759
Male	0	0	0	0
Race/Ethnicity, Customized [units: participants]
Asian	151	27	165	343
Black	136	5	167	308
Hispanic American	567	93	566	1226
Native American	10	2	10	22
White	1600	171	1558	3329
Other - Unspecified	259	6	266	531

[1]	Although the upper age limit for this study was 23 years old, four subjects aged 24 were randomized into the study.

Outcome Measures

Show All Outcome Measures

1. Primary:

Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer [ Time Frame: Follow-up through end of study (4 years) ]

Show Outcome Measure 1

2. Primary:

Incidence of HPV 6/11/16/18-related External Genital Lesions (EGL) [Genital Warts, Vulvar/Vaginal Intraepithelial Neoplasia (Any Grade), Vulvar/Vaginal Cancer] [ Time Frame: Follow-up through end of study (4 years) ]

Show Outcome Measure 2

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	No text entered.
Additional Description	Number of subjects at risk included randomized subjects who had follow-up. Differing numbers of subjects were at risk for serious vs. other adverse experiences (AEs) as both serious and non-serious AEs were collected in the base period and only serious AEs were collected in the extension period.

Reporting Groups

	Description
Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Group 2 - Base Study Monovalent HPV (Type 16) Vaccine	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with the Monovalent (HPV 16) HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Monovalent (HPV 16) HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Group 3 - Base Study Placebo	The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
Group 4 - Quadrivalent Human Papillomavirus Vaccine Extension	This group was comprises subjects from (1) Group 1 who received less than 3 doses of Quadrivalent HPV vaccine during the base study; (2) Group 2 subjects who received Monovalent vaccine; and (3) Group 3 placebo subjects from the base study). Subjects enrolled in the extension were vaccinated with the Quadrivalent HPV vaccine during the study extension. No data on non-serious adverse events were collected on this group during the extension study, hence no data are entered for them in the table.

Serious Adverse Events

	Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine	Group 2 - Base Study Monovalent HPV (Type 16) Vaccine	Group 3 - Base Study Placebo	Group 4 - Quadrivalent Human Papillomavirus Vaccine Extension
Total, serious adverse events
# participants affected / at risk	50/2674 (1.87%)	4/299 (1.34%)	45/2673 (1.68%)	5/139 (3.60%)
Blood and lymphatic system disorders
Anaemia ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Gastrointestinal disorders
Gastric Ulcer ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	0/2673 (0.00%)	1/139 (0.72%)
Hepatobiliary disorders
Cholecystitis ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Cholelithiasis ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Immune system disorders
Allergy to vaccine ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	0/2673 (0.00%)	1/139 (0.72%)
Infections and infestations
Anogenital warts ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Appendicitis ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Breast abscess ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	1/299 (0.33%)	0/2673 (0.00%)	0/139 (0.00%)
Endometritis decidual ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Enterocolitis infectious ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	1/299 (0.33%)	0/2673 (0.00%)	0/139 (0.00%)
Gastroenteritis ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	1/139 (0.72%)
Pelvic inflammatory disease ^{* 1}
# participants affected / at risk	2/2674 (0.07%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Pharyngitis ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	0/2673 (0.00%)	1/139 (0.72%)
Post procedural infection ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Pyelonephritis ^{* 1}
# participants affected / at risk	2/2674 (0.07%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Tonsillitis streptococcal ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Urinary tract infection ^{* 1}
# participants affected / at risk	2/2674 (0.07%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Varicella ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Injury, poisoning and procedural complications
Abdominal injury ^{† 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Accidental poisoning ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Head injury ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Injury ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Multiple injuries ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Operative haemorrhage ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Overdose ^{* 1}
# participants affected / at risk	16/2674 (0.60%)	2/299 (0.67%)	21/2673 (0.79%)	0/139 (0.00%)
Post procedural haemorrhage ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	3/2673 (0.11%)	0/139 (0.00%)
Road traffic accident ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Metabolism and nutrition disorders
Dehydration ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Nervous system disorders
Convulsion ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Dizziness ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Facial palsy ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Headache ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Syncope ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Transient ischemic attack ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	0/2673 (0.00%)	1/139 (0.72%)
Pregnancy, puerperium and perinatal conditions
Abortion threatened ^{† 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Breech presentation ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Cephalo-pelvic disproportion ^{* 1}
# participants affected / at risk	2/2674 (0.07%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Cervix dystocia ^{* 1}
# participants affected / at risk	4/2674 (0.15%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Failed induction of labor ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Failed trial of labor ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Fetal distress syndrome ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Fetal malposition ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Oligohydramnios ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Pre-eclampsia ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	3/2673 (0.11%)	0/139 (0.00%)
Premature labor ^{* 1}
# participants affected / at risk	2/2674 (0.07%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Premature rupture of membranes ^{* 1}
# participants affected / at risk	2/2674 (0.07%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Prolonged labor ^{* 1}
# participants affected / at risk	2/2674 (0.07%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Transverse presentation ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Psychiatric disorders
Completed suicide ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Renal and urinary disorders
Renal failure ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Reproductive system and breast disorders
Cervix haemorrhage uterine ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Asthma ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Bronchospasm ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Hyperventilation ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)
Pulmonary embolism ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Vascular disorders
Deep vein thrombosis ^{* 1}
# participants affected / at risk	0/2674 (0.00%)	0/299 (0.00%)	1/2673 (0.04%)	0/139 (0.00%)
Hypotension ^{* 1}
# participants affected / at risk	1/2674 (0.04%)	0/299 (0.00%)	0/2673 (0.00%)	0/139 (0.00%)

†	Events were collected by systematic assessment
*	Events were collected by non-systematic assessment
1	Term from vocabulary, MedDRA 11.1

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Executive Vice President, Clinical and Quantitative Sciences
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372

Publications:

Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine. J Infect Dis. 2009 Jan 26; [Epub ahead of print]

Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10;356(19):1928-43.

Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007 May 19;369(9574):1693-702.

Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER. Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation. Value Health. 2008 May 16; [Epub ahead of print]

Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, Barr E. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008 Mar 15;122(6):1311-8.

FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007 Nov 15;196(10):1438-46. Epub 2007 Oct 31.

Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007 Jun 2;369(9576):1861-8.

Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007 Oct 15;196(8):1153-62. Epub 2007 Sep 17.

Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1777-84.

Publications automatically indexed to this study:

Clark LR, Myers ER, Huh W, Joura EA, Paavonen J, Perez G, James MK, Sings HL, Haupt RM, Saah AJ, Garner EI. Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health. 2013 Mar;52(3):322-9. doi: 10.1016/j.jadohealth.2012.07.003. Epub 2012 Aug 15. PubMed PMID: 23299013.

Ruiz ÁM, Ruiz JE, Gavilanes AV, Eriksson T, Lehtinen M, Pérez G, Sings HL, James MK, Haupt RM; FUTURE I and II Study Group. Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease. J Infect Dis. 2012 Dec 15;206(12):1887-96. doi: 10.1093/infdis/jis612. Epub 2012 Oct 12.

Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM; FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012 Mar 27;344:e1401. doi: 10.1136/bmj.e1401.

Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, Joura EA, Giacoletti KE, Radley DR, James MK, Saah AJ, Sings HL; FUTURE I and II Investigators. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer. 2011 Dec 1;129(11):2632-42. Epub 2011 Apr 13.

Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J; FUTURE I and II Study Group. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect. 2011 Aug;87(5):372-6. Epub 2011 Apr 6.

Ault KA, Joura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Sings HL, Harkins K, Rutkowski MA, Haupt RM, Garner EI; FUTURE I and II Study Group. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer. 2011 Mar 15;128(6):1344-53. Epub 2011 Jan 12.

FUTURE I/II Study Group; Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010 Jul 20;341:c3493.

Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, Zhou H, Haupt RM, Garner EI; Quadrivalent Human Papillomavirus Vaccine Phase III Investigators. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009 Dec;114(6):1179-88.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009 Apr 1;199(7):926-35.

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009 Apr 1;199(7):936-44.

Six L, Leodolter S, Sings HL, Barr E, Haupt R, Joura EA. Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial. Wien Klin Wochenschr. 2008;120(21-22):666-71.

Responsible Party:	Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier:	NCT00092521 History of Changes
Other Study ID Numbers:	2004_081, V501-013
Study First Received:	September 23, 2004
Results First Received:	August 3, 2009
Last Updated:	April 7, 2010
Health Authority:	United States: Food and Drug Administration

To Top